Tonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Purchases 1,415 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Carolyn Taylor bought 1,415 shares of the stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $10.55 per share, with a total value of $14,928.25. Following the completion of the purchase, the director directly owned 1,833 shares of the company’s stock, valued at approximately $19,338.15. This trade represents a 338.52% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tonix Pharmaceuticals Trading Up 1.5%

Shares of TNXP opened at $11.52 on Tuesday. The firm has a market capitalization of $183.63 million, a P/E ratio of -0.80 and a beta of 1.67. Tonix Pharmaceuticals Holding Corp. has a 12-month low of $10.03 and a 12-month high of $69.97. The firm has a fifty day moving average price of $12.99 and a 200-day moving average price of $14.92.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). The company had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.13 million. Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TNXP has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. TD Cowen raised shares of Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Wall Street Zen lowered shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Trading of Tonix Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE lifted its position in shares of Tonix Pharmaceuticals by 101.1% during the first quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock valued at $838,000 after buying an additional 30,644 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tonix Pharmaceuticals by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 30,426 shares of the company’s stock valued at $418,000 after buying an additional 6,362 shares during the last quarter. SJS Investment Consulting Inc. purchased a new stake in shares of Tonix Pharmaceuticals during the first quarter valued at about $138,000. Man Group plc purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $288,000. Finally, Engineers Gate Manager LP lifted its position in shares of Tonix Pharmaceuticals by 63.7% during the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after buying an additional 5,550 shares during the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.